Team Leader of the Consciousness Disorder Treatment Collaborative Group, Craniocerebral Trauma Center, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Attending Neurosurgeon; Joint Ph.D. Trained by Shanghai Jiao Tong University and Massachusetts Institute of Technology; Specializes in surgical treatment of coma, hemiplegia, paraplegia, and other diseases caused by various etiologies In October 2015, Dr. Yang Xi received funding from the China Scholarship Council to pursue advanced training in nanomedicine research and development at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology in the United States of America. He has long been engaged in molecular, genetic, and nanomedicine research and development for neurological diseases, and has unique insights into the occurrence, progression, targeted therapy, and immunotherapy of central nervous system diseases. During his work at the Koch Institute for Integrative Cancer Research at MIT, he participated in research on the therapeutic effects of nano-targeted drugs and gene therapy on various neurological injuries and tumors. To date, Dr. Yang Xi has published more than 30 SCI journal papers, among which 10 SCI papers have been published as first author (including co-first author) and corresponding author (including co-corresponding author), with 1 invention patent and 1 utility model patent. Honors received over the years are as follows: 2018 Renji Hospital Outstanding Resident Physician 2018 Second Prize in the National Glioma Case Competition "Ningshen Jujiao" 2019 Third Place in the Shanghai Young Neurosurgeons Case Competition 2020 Champion in the Comprehensive Knowledge Group of the National Neurosurgery Specialty Training Physician Competition He has presided over 1 Youth Fund project of the National Natural Science Foundation of China and 1 Clinical Research Fund project of the Shanghai Municipal Health Commission. He has published more than 10 SCI papers as first or corresponding author, which have been cited more than 400 times, with an H-index of 12.